Default: Liver Transplantation

ISSN: 1527-6465

Journal Home

Journal Guideline

Liver Transplantation Q1 Unclaimed

John Wiley and Sons Ltd United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Liver Transplantation is a journal indexed in SJR in Hepatology and Surgery with an H index of 150. It has a price of 2395 €. It has an SJR impact factor of 1,814 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,814.

Liver Transplantation focuses its scope in these topics and keywords: liver, transplantation, hepatocellular, impact, disease, living, pediatric, failure, autoimmune, outcome, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Price

2395 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

Liver Transplantation

1,814

SJR Impact factor

150

H Index

246

Total Docs (Last Year)

663

Total Docs (3 years)

5580

Total Refs

2091

Total Cites (3 years)

410

Citable Docs (3 years)

3,04

Cites/Doc (2 years)

22,68

Ref/Doc

Aims and Scope


liver, transplantation, hepatocellular, impact, disease, living, pediatric, failure, autoimmune, outcome, factors, donor, carcinoma, common, diseasesa, effects, cohort, classificationbeneficial, antidonor, approach, bacteremia, barcelona, bowel, branchedchain, burden, carcinomafulminant, cholangitis,



Best articles by citations

Orthotopic liver transplantation for alcoholic liver disease: A retrospective analysis of survival, recidivism, and risk factors predisposing to recidivism

View more

Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: Outcome of 7 patients from the Bonn cohort

View more

The use of hepatitis C-infected grafts in liver transplantation

View more

Ethical issues surrounding adult-to-adult living donor liver transplantation

View more

Hepatic and intestinal schistosomiasis after orthotopic liver transplant

View more

Rejection of pig liver xenografts in patients with liver failure: Implications for xenotransplantation

View more

Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease

View more

Rho-kinase inhibitor targeting the liver prevents ischemia/reperfusion injury in the steatotic liver without major systemic adversity in rats

View more

Renal outcomes after liver transplantation in the model for end-stage liver disease era

View more

Hepatopulmonary syndrome after living donor liver transplantation and deceased donor liver transplantation: A single-center experience

View more

Influenza Infection in Patients Before and After Liver Transplantation

View more

Differences in lymphocyte gene expression between tolerant and syngeneic liver grafted rats

View more
SHOW MORE ARTICLES

Cognitive dysfunction and health-related quality of life in long-term liver transplant survivors

View more

Recurrent hepatitis C virus infection after orthotopic liver transplantation

View more

Bronchiolitis obliterans organizing pneumonia after orthotopic liver transplantation

View more

Graft-versus-host disease following living donor liver transplantation

View more

Is the Cost of Adult Living Donor Liver Transplantation Higher Than Deceased Donor Liver Transplantation?

View more

Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation

View more

Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: Not just a cholestatic problem

View more

Refinement of venous reconstruction using cryopreserved veins in right liver grafts

View more

Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States

View more

Treatment of patients with hepatitis C virus on the waiting list

View more

Host and donor risk factors before and after liver transplantation that impact HCV recurrence

View more

Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection

View more

Comments

No comments ... Be the first to comment!

FAQS